Image Credit: Canva
Can a toothache be the reason for someone's cancer? An England based doctor and health content creator @Choji_ES who posts on X, formerly Twitter on reproductive health related content revealed a case where a man went to the dentist due to pain in his jaw and when the tooth was pulled out, a cancer was found in his private part.
The same case also been mentioned by Baridueh Badon (MD, MSc, MBA), who allows posts healthcare content on the same microblogging platform, by the username @BadonB.
In this case, a man went to a dentist for a simple toothache, only to discover that he had cancer. This happened to a 78-year-old healthy man, who suffered pain in his lower jaw and noticed a loose tooth. When he went to the dentist, he decided to get his tooth remove to ease his pain. However, despite the removal, his jaw started to swell again. Confused, the man was recommended for a CT scan and something unexpected happened.
It was Metastatic Prostate Cancer.
As per an African proverb, it is true that the head and the body are one; what affects one may touch the other.
Prostate cancer starts in the prostate gland, which is a part of a man's reproductive system. When it spreads to other parts of the body, like the jaw, it is called metastatic prostate cancer. But, why exactly the jaw? This is because the jawbone is rich in blood and active bone marrow, which makes it a comfortable place for cancer cells to settle and grow.
As per a 2023 study in the Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, titled Mandibular metastasis from prostate cancer that clinically mimicked osteosarcoma: A case report, noted that in men, 11% of jawbone metastases originated from the prostate gland.
Warning Signs Dentists Look For:
These may seem minor, but they could hint at something serious. Early detection is life-saving.
Prostate cancer is the 4th common cancer globally and is most prone to men who are over 40. Every year, it claims about 400,000 lives worldwide.
Earlier in November, six-time Olympic cyclist Sir Chris Hoy was diagnosed with stage-4 prostate cancer, which was announced in February. This six-time Olympic champion revealed that he had a pain in his shoulder when he was 47, which did not go away. "I was still lifting weights in the gym, still physically active. You are used to having aches and pains, but this one did not go away."
The prostate is a small walnut-shaped gland in men that produces seminal fluid that nourishes and transports sperm. It occurs when abnormal cells form and grow in that gland.
Experts say that not all prostate cancer is deadly. There are cancers that are slow-growing and will not affect a man's lifespan, which is found in 1 in 3 men over 50. Then there is a small number of very aggressive prostate cancers which move quickly and cause harm, this is why regular screening is important.
Chris too has called for more, younger men to be tested, including those with a family history of the disease.
Credit: AI
I've spent over three decades treating heart disease, and in that time, I've seen the same misunderstanding come up again and again, across different patients, different generations, different backgrounds. It's the one that delays diagnosis more than any other. Ask most people what menopause changes, and they'll talk about hot flashes, mood swings, or sleep. Ask me, and I'll tell you it changes something just as important: a woman's heart.
I believe menopause should be treated as a cardiovascular milestone, not just a reproductive one. We talk to women a great deal about bone density, hormonal symptoms, and fertility. We talk far less about what's happening quietly inside their arteries during this same period. That gap in the conversation is costing us early diagnoses. In some cases, it's costing lives.
To understand why, it helps to look at what protects a woman's heart in the first place. For most of her reproductive years, estrogen acts almost like a quiet guardian in the background, keeping the endothelium — the inner lining of blood vessels — working well, and supporting the release of nitric oxide, which helps arteries stay relaxed and open. This is a big reason heart attacks are fairly uncommon in women before menopause, compared to men of a similar age.
Menopause takes that buffer away, slowly, not all at once. The shift usually starts during perimenopause, often well before periods actually stop. LDL, the harmful cholesterol, tends to rise; HDL, the protective kind, often falls. Blood pressure that used to be easy to control starts creeping higher. Arteries stiffen, insulin resistance sets in, and fat tends to shift toward the belly, carrying its own inflammatory effect on blood vessels. None of this feels dramatic on any single day. It just builds, quietly, year after year — enough that by ten to fifteen years past menopause, a woman's heart risk has often caught up to, and sometimes overtaken, a man's of the same age.
Also read: Lifestyle Genetics And Hormones: Understanding The Interplay Of Risk Factors For Ovarian Cancer
Some argue this is simply age catching up, and that menopause gets blamed unfairly. There's truth in that — age alone stiffens arteries in everyone. But in my experience, losing estrogen compresses those changes into a much shorter stretch of time. It isn't one factor or the other; it's ageing, sped up by a hormonal shift arriving right in the middle of life.
That said, menopause alone doesn't determine a woman's future with heart disease. It sets the stage, but daily habits decide how the story plays out. Smoking, inactivity, weight around the middle, a diet heavy in processed food, unchecked blood pressure and blood sugar, chronic stress, poor sleep, and skipped check-ups all add their share. The reassuring part is that nearly everything on that list can be changed. I've watched patients shift their own trajectory with fairly ordinary steps — walking regularly, eating simply, sleeping better, getting basic tests done once a year.
Also read: Mood Swings, Anxiety & Brain Fog During Menopause? Expert Recommends Looking Beyond Hot Flashes
What troubles me most in practice is how often real cardiac symptoms get mistaken for "just menopause." Chest pressure rather than sharp pain. New breathlessness during simple activity. Fatigue that doesn't lift with rest. Pain in the jaw, upper back, or between the shoulder blades instead of the classic left-arm pain. Palpitations that don't settle. A few months ago, a woman in her early fifties came to me convinced she had acidity — tightness in the chest, breathlessness on stairs, an occasional fluttering heartbeat. An angiogram showed a significant coronary blockage. "I thought heart problems were a man's disease," she told me. I hear some version of that sentence often, and it worries me every time.
My advice to patients is simple: perimenopause is the right time for an honest conversation with a doctor about the heart, not after something has gone wrong. That means a blood pressure check, a proper lipid profile, blood sugar and HbA1c testing, and a baseline ECG — with an echocardiogram, stress test, or coronary calcium score for those with added risk factors.
Menopause changes a great deal about a woman's body. Her heart is one of those things, whether she's thinking about it or not. Don't wait for a scare to start the conversation. Start it now, while there's still so much you can do.
Credit: iStock
For decades, many cancer patients in India have lived with a frightening belief — that a biopsy can make cancer spread. This misconception continues to delay diagnosis, often costing patients the opportunity for timely treatment. This is one of the most common fears I encounter in clinic.
Almost every week, someone tells me, 'Doctor, if you cut it, it will spread.' Families repeat it, neighbors reinforce it, and patients postpone the test. Actually, this concern is linked to a genuine scientific phenomenon known as needle-tract seeding. These phenomena suggest that a few tumor cells may be displaced along the path of the biopsy needle.
However, this event is extremely uncommon and should not be confused with cancer spreading. Seeding is not the same as spreading. A few displaced cells sitting in a needle track are not a metastasis.
Published studies estimate the risk of needle-tract seeding to be extremely low. A 2015 systematic review reported the overall incidence to be below one percent, while more recent reviews, including a 2024 analysis of breast needle biopsy, found no evidence that diagnostic biopsies increase cancer recurrence or reduce long-term survival.
If tumor cells are displaced during a biopsy, they are usually removed when the tumor is surgically excised. In many cases, radiotherapy, systemic treatment and the body's own immune system also eliminate these cells.
In many tier-two and tier-three cities, it takes two to three weeks to reach final report to the treating doctor. During that period, the untreated cancer continues to grow naturally. The patient does not see natural history. He sees cause and effect. The biopsy happened; the lesion grew. The conclusion writes itself — and it is wrong. This delay unintentionally reinforces the misconception that the biopsy triggered the growth, when in reality the cancer was progressing on its own.
At the same time, every tissue injury, including a biopsy, activates the body's wound-healing response, leading to inflammation and new blood vessel formation. Laboratory and animal studies suggest that this temporary inflammatory environment may favor tumor cells. However, these findings have not translated into poorer outcomes for patients. So, the fear is not irrational. It is simply misdirected, and it is mis proportioned.
The diagnosis is not the danger. The delay is. Biopsy helps precision oncology. It helps deciding the treatment approach. Without this we would be treating in the dark.
The consequences of delaying diagnosis are serious. Patients of oral cancer diagnosed while the disease is still localized have a five-year survival rate of nearly 79 per cent. Once the cancer spreads to distant organs, survival drops to around 19 per cent. Unfortunately, nearly two-thirds of oral cancer patients in India are still diagnosed at an advanced stage.
Credit: iStock/JamPress
A UK woman has claimed that Wegovy and Mounjaro, the blockbuster GLP-1 weight-loss drugs from Novo Nordisk and Eli Lilly, did not help her lose much weight despite more than a year of treatment.
Karen Lay, 56, from Essex, spent £4,000 on the medications, hoping they would help her slim down from 16 stone (224 pounds). However, after 15 months, she lost less than a stone, despite eating very little.
Lay now says the injections were far from a "magic fix" and credits a structured diet for helping her lose two stone, the Daily Mail reported.
Lay began taking Wegovy in late 2023 after trying several diets without success. She remained on the medication for nine months, even though she felt something "wasn't right."
“My appetite reduced slightly at first,” Lay, a financial services worker, was quoted as saying. “But not enough to make a meaningful difference, so I increased the dosage each month.”
After seeing limited results with Wegovy, Lay stopped the medication for four weeks before switching to Mounjaro. She described the transition period as experiencing the "worst food noise" and said she gained more than seven pounds while waiting for the first drug to clear from her system.
Lay then spent six months on Mounjaro but said she was "barely eating" and still failed to achieve the weight loss she expected.
“I only lost seven pounds,” she said. “I realised the injections simply weren't effective for me and something had to change.”
Her doctor eventually advised her to stop taking the medication because they were concerned she was not eating enough, the report said.
Lay said the experience was “emotionally exhausting and honestly quite soul-destroying,” and "deeply disheartening.” Watching others succeed on the drugs made it even harder.
After discontinuing the injections, Lay adopted a very low-calorie diet with support from expert nutrition advisers who provided personalized guidance.
“Once the medication was fully out of my system, I began to feel genuinely better,” Lay said, adding that her “energy returned, digestion improved, and the constipation disappeared.”
Within a year, she went from a dress size 18 to size 12, the smallest she had been in 17 years, with her weight falling to 13 stone 5 pounds, the report said.
Clinical trials have shown that most people taking these medications experience substantial weight loss.
Around 2.5 million adults in the UK are estimated to be using weight-loss injections, while hundreds of thousands have signed up for the newly approved Wegovy pill, which was rolled out by the NHS this month.
But some people are 'non-responders', meaning they do not lose a meaningful amount of weight despite treatment. Research earlier this year found that around one in 10 people taking GLP-1 medications are considered non-responders.
Although GLP-1 receptor agonists have delivered remarkable results for many people, they do not work the same way for everyone. Obesity is a complex condition influenced by brain signaling, hormones, genetics, and metabolism, meaning treatment responses can vary significantly. Possible reasons include:
© 2024 Bennett, Coleman & Company Limited